Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY – MD Anderson discusses the combination of Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer with an 8% Response Rate with an Overall Survival of 13-14 months. Recorded at ASCO GI 2018.
Combo Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer 8Response Rate with an Overall Survival of 13-14 months
